<DOC>
	<DOCNO>NCT01972776</DOCNO>
	<brief_summary>This 2 Part study . Part 1 safety tolerability study GOLD I-III COPD patient . Part 2 efficacy study GOLD I-III COPD patient .</brief_summary>
	<brief_title>A Safety , Tolerability Efficacy Study Chronic Obstructive Pulmonary Disease ( COPD ) Patients With QBM076 .</brief_title>
	<detailed_description>Part 1 double-blind , randomize , placebo-controlled , non-confirmatory study chronic bronchitis COPD patient . Part 1 consisted 27-days screening period , one baseline period 1 day , 13 day bid dose study treatment , morning treatment Day 14 , follow visit Days 15 - 17 , follow Study Completion evaluation . Twenty-seven patient randomize 3:1 ratio 3 cohorts.. Part 2 double-blind , randomize , placebo-controlled , non-confirmatory study Gold spirometry grade I-III COPD patient . Part 2 consisted 20 day screen period , 9 day run period , one baseline period 1 day , 55 day bid dosing , morning dose Day 56 , follow Study Completion evaluation . It plan randomize 90 patient 2:1 ratio , part 2 terminate 21 patient enrol . Three 21 part 2 patient experienced moderate severe ( 17-fold ) asymptomatic reversible elevation liver transaminase level 3 week treatment QBM076 150 mg twice daily . Two patient liver transaminase level high enough report serious adverse event suspect related study drug .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Part 1 : Patients , smoker exsmokers stable chronic bronchitis GOLD class IIII chronic obstructive pulmonary disease ( COPD ) ; force expiratory volume 1 second ≥40 % predict forced expiratory volume 1 second : force vital capacity ratio ≤0.7 post bronchodilator , respectively ; diffuse capacity lung carbon monoxide ≥40 % ; stable medical regimen least 4 week prior screen . Current smoker enrol currently smoke ≤1ppd last 3 month . Part 2 : Patients , smoker exsmokers GOLD spirometry class IIII COPD ; stable medical regimen least 4 week prior screen ; high sensitivity C reactive protein≥1.5 mg/L ; force expiratory volume 1 second ≥30 % predict forced expiratory volume 1 second : force vital capacity ratio ≤0.7 post bronchodilator , respectively ; mean lung clearance index 2.5 % ≥8 ; Exsmokers least 10 pack year smoke history ; current smoker least 10 pack year smoke history smoke ≤ 1ppd average last 3 month . ; evidence air trap base radiologic criterion ; woman child bear potential use effective method contraception Part 1 : Gold Class IV COPD , moderate significant emphysema , evidence malignancy ; medication consider potential drug drug interaction ; creatinine clearance &lt; 30ml/min ; 1 exacerbation require antibiotic oral steroid and/or hospitalization within 3 month screen ; woman child bear potential • Part 2 : Gold spirometry grade IV COPD ; medication consider potential drug drug interaction ; serum creatinine ≥1.9 mg/dL ; 1 exacerbation require antibiotic oral steroid within 2 month and/or hospitalization within 3 month screen ; malignancy ; evidence severe emphysema determine HRCT ; use oral steroid , theophylline , phosphodiesterase4 inhibitor oral antibiotic use ( eg.macrolides )</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>COPD , inflammation , small airway , LCI , PFTs , lung heterogeneity</keyword>
</DOC>